schumer-8047384In a press conference at Albany Medical Center on Monday, Senator Chuck Schumer deplored what he called a “dramatic cut to upstate New York hospitals,” which he claimed would force layoffs and threaten “critical care services such as cancer treatment, addiction treatment and prescription drug access.”

“NY hospitals stand to lose more than $1.7 billion, Schumer says,” was one of the many headlines coming out of the event.

The senator’s depiction of a complex policy change was alarmist and misleading.

What Schumer neglected to mention is that 20 percent of that $1.7 billion (which is a 10-year figure, by the way) will flow to local Medicare recipients. The “cut” he’s talking about is a reduction in the hefty markups that Medicare previously paid hospitals for drugs that are discounted by law, and that reduction also means lower copayments for patients.

An alternate headline could have read: “Schumer opposes lower drug costs for New York seniors.”

At issue is the so-called 340B program, a federal law dating back to 1992 that requires all pharmaceutical manufacturers doing business with Medicaid to provide 20 percent to 50 percent discounts on the drugs they sell to certain hospitals. Originally targeted to safety-net institutions serving the poor, the program has grown to cover 40 percent of all hospitals.

The rules of the program do not require that the savings be passed along to customers, enabling hospitals to charge a markup and use the money however they like. Medicare in particular previously had a policy of paying its usual reimbursement rates to 340B hospitals, regardless of the discounts, a policy that has cost the federal government billions of dollars a year. Hospital officials insist they have put the proceeds to good use, but they’re also not required to publicly account for how they are spent.

In effect, 340B has become a general subsidy for eligible hospitals with little relation to need and minimal oversight. Meanwhile, there’s evidence that the perverse incentives of 340B have led to overutilization of high-priced drugs and driven up the cost of cancer treatment. There have been widespread calls for reform.

The CMS rule change, finalized in November 2017, reduces how much Medicare reimburses hospitals for drugs obtained through the program, from 6 percent above a benchmark known as “average sale prices” to 22.5 percent below the benchmark. The basic structure of the program, including the mandatory discounts by manufacturers, was left intact.

In effect, CMS is forcing hospitals to share part of their savings with Medicare, as other payers have done previously. As a byproduct, the cost-sharing paid by Medicare recipients—typically about 20 percent of the total—will decline as well.

Avalere has estimated that the Medicare program will save $1.3 billion nationwide this year, and Medicare consumers will save $325 million. In New York, which will see the third-largest impact, Avalere estimated Medicare will pay hospitals $62 million less, and consumers will pay $16 million less.

Schumer used a higher estimate of $1.7 billion in losses to New York hospitals over 10 years, for which his press release did not cite a source.

He said Ellis Hospital stood to lose $23 million—but, again, that’s a 10-year figure, which Schumer used for no evident reason other than making the numbers look bigger. At an average of $2.3 million per year, that would amount to one-half of 1 percent of Ellis’ patient revenue, which was $426 million as of 2017.

Albany Med’s estimated 340B loss, which Schumer put at $11.5 million over 10 years, would equate annually to roughly one-tenth of 1 percent of the hospital’s patient revenues, which were $1.1 billion in 2016.

Schumer could have faulted CMS for not going far enough—for shifting money around rather than directly addressing the program’s core flaws. He could have highlighted the uneven effects of the change, which may present a serious issue for some providers. But to frame modest cost-cutting as a dire threat to every affected hospital—and raise a general alarm about layoffs and service cutbacks—was a disservice to the public.

About the Author

Bill Hammond

As the Empire Center’s senior fellow for health policy, Bill Hammond tracks fast-moving developments in New York’s massive health care industry, with a focus on how decisions made in Albany and Washington affect the well-being of patients, providers, taxpayers and the state’s economy.

Read more by Bill Hammond

You may also like

Budget deal increases state-share Medicaid spending by 13 percent

(This post has been updated to correct errors.) Albany's newly enacted budget appears to increase the state share of Medicaid spending by $4.2 billion or 13 percent, contin Read More

Hospital Lobby’s TV Campaign Spreads Misinformation About Medicaid

As New York's health-care industry agitates for more money from the state budget, two of its most influential lobbying groups are airing TV ads that make alarmist and inaccurate claims about Medicaid. Read More

Hochul’s ‘Pay and Resolve’ Push for Hospitals Triggers Déjà Vu

Two years ago last week, I wrote in the Daily News about how then-Governor Andrew Cuomo was pushing a costly change to insurance law on behalf of a hospital group that had supported his campaign through a fund-rai Read More

While pleading for money in Albany, hospitals and nursing homes spend at the bargaining table

Friday's announcement of an amended labor contract for New York City-area hospitals and nursing homes sends a contradictory message about the financial condition of the state's health-care industry. Read More

Hospital group features a misleading statistic in its budget testimony

During testimony on the state budget last week, a hospital industry official made an attention-grabbing but misleading claim – that New York's Medicaid payments to providers are "the worst in the United States." Read More

New York’s pricey hospitals draw pushback from labor

A City Council hearing in Manhattan on Thursday promises a rare scene in New York politics: hospitals playing defense. The council is debating whether to establish a watchdog agency focused on the high price of hospital care in New York, with a goal of helping the city and other employers contain the rapidly rising cost of health benefits for workers. Read More

The Hochul administration seeks more federal money for its overfunded Essential Plan

In a move that ought to raise eyebrows in Washington, the Hochul administration is requesting additional federal money for New York's Essential Plan, which is already sitting on more than $9 billion after years of running a multi-billion-dollar surplus. Read More

Hochul’s agenda mostly sidesteps health care

Governor Hochul gave health care surprisingly little attention in her State of the State speech on Tuesday – a sign that taking on dysfunction in one-sixth of the state's economy ranks low on her list of priorities. Read More

Empire Center Logo Enjoying our work? Sign up for email alerts on our latest news and research.
Together, we can make New York a better place to live and work!